VanEck Pharmaceutical ETF (NASDAQ:PPH – Get Free Report) shares saw strong trading volume on Friday . 102,163 shares changed hands during mid-day trading, a decline of 32% from the previous session’s volume of 149,905 shares.The stock last traded at $86.70 and had previously closed at $88.17.
VanEck Pharmaceutical ETF Trading Down 1.8 %
The firm has a market capitalization of $639.90 million, a price-to-earnings ratio of 21.04 and a beta of 0.72. The stock’s fifty day moving average price is $93.68 and its two-hundred day moving average price is $93.02.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in PPH. Comerica Bank raised its position in VanEck Pharmaceutical ETF by 39.4% during the 1st quarter. Comerica Bank now owns 1,337 shares of the company’s stock worth $121,000 after buying an additional 378 shares during the last quarter. Renaissance Technologies LLC raised its holdings in VanEck Pharmaceutical ETF by 85.0% during the second quarter. Renaissance Technologies LLC now owns 25,900 shares of the company’s stock worth $2,369,000 after purchasing an additional 11,902 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in VanEck Pharmaceutical ETF by 1.7% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 160,039 shares of the company’s stock valued at $14,641,000 after purchasing an additional 2,694 shares during the period. CWM LLC purchased a new stake in VanEck Pharmaceutical ETF in the 2nd quarter valued at approximately $55,000. Finally, Envestnet Portfolio Solutions Inc. purchased a new stake in VanEck Pharmaceutical ETF in the 2nd quarter valued at approximately $211,000.
About VanEck Pharmaceutical ETF
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Featured Stories
- Five stocks we like better than VanEck Pharmaceutical ETF
- The 3 Best Blue-Chip Stocks to Buy Now
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- 3 Stocks to Consider Buying in October
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- How to Calculate Return on Investment (ROI)
- Time to Load Up on Home Builders?
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.
